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Purpose: X-linked agammaglobulinemia (XLA) is a humoral
immunodeficiency disease caused by a mutation in the Bruton
tyrosine kinase (BTK) gene resulting in defective B cell
differentiation. Because it is a relatively rare disorder, it is
difficult for clinicians to have a comprehensive understanding
of XLA due to a lack of exposure to the disease. Clinical
presentations of patients with XLA were analyzed and
discussed to improve care plans. Materials and Methods:
During a 20 year period, from January 1987 to June 2006, a
total of 19 patients were diagnosed as XLA in the Department
of Pediatrics at Severance Hospital, Seoul, Korea. A
retrospective analysis of the clinical presentations of those
patients was performed. Results: The mean age of the XLA
patients included in the study was 4.89 years, with a range
of 6 months to 13 years. Twelve patients were diagnosed
before age 5, while the other 7 patients were diagnosed after
age 5. Recurrent infections observed in the patients included
pneumonia, acute otitis media, septic arthritis, skin infection,
sepsis, sinusitis, acute gastroenteritis, cervical lymphadenitis,
epididymitis, meningitis, osteomyelitis, urinary tract infection
and encephalitis. Frequency of admissions was variable from
0 to 12 times, depending on the time at which immunoglobulin
therapy was started. Six cases had family histories positive for
XLA. BTK gene mutations were found in 8 cases.
Conclusion: The overall prognosis of XLA is good as long as
patients are diagnosed and treated early with regular intra
venous gamma globulin therapy before the sequelae of
recurrent infections appear.
Key Words: Agammaglobulinemia, Bruton’s tyrosine kinase,
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INTRODUCTION
X-linked agammaglobulinemia (XLA) is a
genetic disorder in which the development of B
cells arrests during differentiation. It has been
shown to be caused by a variety of mutations in
the gene encoding Bruton tyrosine kinase (BTK).1-3
BTK is a signal-transducing protein expressed in
all hematopoietic lineages, except in T cells and
NK cells.2 It is composed of five distinct
structural domains: the pleckstrin homology
(PH), Tec homology (TH), Src homology (SH) 3,
SH2, and catalytic kinase (SH1) domains.4 XLA is
often characterized by recurrent bacterial
infections due to a decrease in the number of B
cells and a subsequent reduction in the level of
serum immunoglobulin.2,3,5,6 The BTK gene has
been mapped to Xq21.3-Xq22, encompassing 37.5
kb and containing 19 exons, and mutations in the
gene are inherited in an X-linked recessive
pattern.7
Since 1952 when the disease was first described
by Bruton,
8
the incidence of XLA has increased
and has been recognized at an earlier age.9 Early
diagnosis has been made possible by genetic
analysis of the BTK gene, available since 1994,
and thus administration of intravenous gamma
globulin therapy (IVGG) can be started earlier.
This treatment has decreased the prevalence of
infections and frequency of hospital admis-
sions.
9,10
Because of the low incidence of this disease
(around 1/200,000 live births11) there are few
reports of XLA in a single institution with the
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exception of the study by Moin, et al., a
retrospective study of 33 XLA patients over a
period of 22 years at one of the largest referral
centers in Iran.12 There are some reports of multi-
center studies, such as those by Winkelstein, et
al.9 in the US, and by Plebani, et al. in Italy.13
This study is the first attempt in South Korea for
a systematic analysis of the natural clinical course
and presentation of the disease. It was
undertaken to increase awareness of XLA in
physicians and to improve care plans through a
better understanding of the clinical courses of the
disease in patients at this institute, one of the
largest tertiary referral centers in South Korea.
MATERIALS AND METHODS
We reviewed the records of 19 patients with
XLA who had been referred to Severance
Children’s Hospital, South Korea from January
1987 to June 2006. The diagnosis of XLA was
made based on standard criteria described below.14
Diagnostic Criteria
Definitive
A male patient with less than 2% CD19 B cells
and at least one of the following findings is
present.
1. Mutation in BTK gene.
2. Absence of BTK mRNA on northern blot
analysis of neutrophils or monocytes.
3. Absence of BTK protein in monocytes or
platelets.
4. Maternal cousins, uncles, or nephews with
less than 2% CD19 B cells.
Probable
A male patient with less than 2% CD19 B cells
in whom all of the following findings are present:
1. Recurrent bacterial infections in the first 5
years of life.
2. Serum IgG, IgM, and IgA more than 2 SD
below normal for the patient’s age.
3. Absent isohemagglutinins and/or poor res-
ponse to vaccines.
4. Other causes of hypogammaglobulinemia
have been excluded.
Possible
A male patient with less than 2% CD19 B cells
in whom other causes of hypogammaglobu-
linemia have been excluded and at least one of the
following findings is present:
1. Recurrent bacterial infections in the first 5
years of life.
2. Serum IgG, IgM, and IgA more than 2 SD
below normal for the age.
3. Absence of isohemagglutinins.
To exclude other causes of hypogammaglobu-
linemia, such as transient hypogammaglobulinemia
of infants, a close follow-up was done by checking
serum IgG, IgA, and IgM levels, by examining B and
T cell subset enumeration (CD19, CD3, CD4, and
CD8) through 2 times of flow cytometric analysis in
all patients, and by confirming the presence of
tonsils. In 8 patients, gene sequencing was
performed to detect BTK mutations using the
method described by Futatani, et al.15
RT-PCR and DNA sequencing
Total RNA was prepared from PBMC using
TRIzol reagent (Life Technologies, Grand Island,
NY) according to the manufacturer’s instructions.
cDNA was synthesized from RNA using reverse
transcriptase. PCR amplification of the BTK cDNA
was performed using seven overlapping PCR
primers as described by Fututani, et al.15 The
resulting PCR products were purified using a DNA
purification system (Promega, Madison, WI).
Direct sequencing of the amplified RT-PCR products
by the dideoxynucleotide chain termination
method was performed using the Sequenase 2.0
kit (USB, Cleveland, OH) and the BigDye terminator
cycle sequencing kit (PE Applied Biosystems,
Foster City, CA) along with an automated Applied
Biosystems PRISM 310 genetic analyzer (PE Applied
Biosystems). Forward and reverse primers for use
in manual DNA sequencing were labeled with -
35S-dATP, and the reaction products were
electrophoresed on denaturing 6% polyacrylamide
gels. Mutated sequences were confirmed by
opposite-strand sequencing or by sequencing
genomic DNA fragments covering intron-exon
boundaries (reference: U78027).
Jin-Kyong Chun, et al.
Yonsei Med J Vol. 49, No. 1, 2008
SSCP and RFLP analyses
For SSCP analysis, 3 L of PCR product wasμ
mixed with 9 L of sample loading buffer (95%μ
formamide, 10 mM NaOH, 0.25% bromophenol
blue, and 0.25% xylene cyanol). The samples were
denatured for 5 min at 100℃ in 1 × sample buffer
(33 mM Tris-sulfate and 7% glycerol, pH 8.3). The
DNA was then resolved by 12% PAGE and
stained using a Silver Stain Plus kit (Bio-Rad,
Hercules, CA, USA). PCR-RFLP was performed
using MboI restriction endonuclease site and
analyzed by 2% agarose gel electrophoresis.
Statistical analysis
Pearson correlation coefficient between the age
of the patient when IVGG treatment was started
and the frequency of admission was calculated in
patients with Bruton disease. The p value was
two-sided, and values less than 0.05 were con-
sidered statistically significant.
RESULTS
There were a total of 19 patients diagnosed as
Bruton disease, with an age distribution at the
time of diagnosis varying from 6 months to 13
years. The mean age at diagnosis was 4.89. Twelve
patients were diagnosed before age 5. The other
7 patients had been transferred from other
hospitals due to recurrent severe infections after
age 5. Serum IgG concentrations ranged from 7 to
88.6 mg/dL, and B cell counts ranged from 0 to
1.9%. Patients 1, 10, and 16 received immuno-
globulin prior to an immune work-up, so their
baseline data were not available. The diagnostic
Table 1. Clinical Features of X-linked Agammaglobulinemia Patients
Patient
Age at Dx.
(months)
IgG
(mg/dL)
IgM
(mg/dL)
IgA
(mg/dL)
CD19 B cell
count (%)
Dx.
criteria
Duration
IVGG (months)
Family
history
1 12 831* (172 - 1069) 17.7 (41 - 173) 22.1 (11 - 106) 0.50 probable 24 +
2 6 63 (172 - 1069) 3.8 (33 - 126) 5.5 (4.4 - 84) 0.80 probable 130 -
3 96 71 (608 - 1572) 16.0 (52 - 242) 11.0 (33 - 236) 0.1 definitive 163 +
4 24 14 (345 - 1236) 6.3 (43 - 207) 9.0 (14 - 159) 0.03 probable 127 -
5 156 67 (639 - 1349) 50.0 (56 - 352) 11.0 (70 - 312) 1.00 definitive Dead (76) +
6 132 58 (639 - 1349) 4.8 (56 - 352) 21.0 (70 - 312) 1.30 definitive 163 +
7 12 23 (172 - 1069) 17.0 (41 - 173) 23.0 (11 - 106) 0.10 probable 76 -
8 12 57 (172 - 1069) 4.5 (41 - 173) 0.5 (11 - 106) 0.30 probable Dead (72) -
9 84 7 (608 - 1572) 17.0 (43 - 207) 25.0 (33 - 236) 0.00 possible 37 -
10 144 561* (639 - 1349) 17.0 (56 - 352) 23.0 (70 - 312) 1.90 possible Irregular -
11 36 33 (345 - 1236) 8.0 (43 - 207) 6.0 (14 - 159) 0.00 probable 73 -
12 24 10 (345 - 1236) 18.2 (43 - 207) 24.8 (14 - 159) 0.08 definitive 8 -
13 7 89 (172 - 1069) 21.2 (43 - 207) 25.4 (11 - 106) 0.90 definitive 30 -
14 48 33 (345 - 1236) - - 1.40 definitive 174 +
15 48 7 (345 - 1236) 17.0 (43 - 207) 23.0 (14 - 159) 0.16 probable 11 -
16 60 1460* (345 - 1236) < 21 (43 - 207) < 23 (14 - 159) 0.30 definitive 3 -
17 84 < 9 (608 - 1572) < 29 (43 - 207) < 29 (33 - 236) 0.00 probable F/U loss -
18 84 15 (608 - 1572) 25.0 (43 - 207) 8.0 (33 - 236) 0.80 definitive 214 +
19 48 50 (345 - 1236) 47.0 (43 - 207) 20.0 (14 - 159) 0.10 probable 173 -
*After immunoglobulin replacement values.
Patients 3 and 6 are siblings.
Dx, diagnosis; F/U, follow up.
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laboratory results are listed in Table 1.
According to diagnostic criteria,14 all patients in
the study were diagnosed as XLA. Eight of the
patients (3, 5, 6, 12, 13, 14, 16, and 18) were
diagnosed as definitive using genetic studies.
Nine of them were diagnosed as probable, and 2
(9 and 10) as possible.
Most of the patients were admitted due to
recurrent bacterial infections; only one case
(patient 3) was revealed to be Bruton disease by
genetic screening because his sibling had been
diagnosed as XLA (patient 6). In the case of
patient 13, his mother had undergone chorionic
villus sampling during her second pregnancy, and
it revealed that the fetus had a BTK gene muta-
tion. The results of gene sequencing are found in
Table 2. A total of 8 cases were part of the BTK
gene study. The most frequent infections, in order
of descending frequencies, were pneumonia, acute
otitis media, septic arthritis, skin infection, sepsis,
sinusitis, acute gastroenteritis, cervical lympha-
denitis, epididymitis, meningitis, osteomyelitis,
urinary tract infection and encephalitis (Table 3).
About 25% of patients had more than one episode
of septic arthritis. At first, primary care physicians
(PCPs) suspected these patients had juvenile
rheumatoid arthritis, and they were treated with
NSAIDs. The PCPs later referred them to the
tertiary care center because there was no clinical
improvement. Synovial fluid cultures revealed the
patients had staphylococcal, pseudomonal, and
mycobacterial infections. Recurring and unusual
Table 2. Summary of Mutations in the Bruton Tyrosine Kinase Gene of the Patients
Patient No. Exon/Intron BTK domain Mutations
14 Intron 1 5' untranslated G to A: point mutation, regulatory defect (+5)
18 Exon 3 PH G54delX56, frame shift and premature termination
3* Intron 6 TH G to A: point mutation splicing error, skipping Exon 6
6* Intron 6 TH G to A: point mutation, same mutation as patient 3
5 Exon 8 SH3 +710 del AGGG: K237delX275, germline mutation
13 Exon 10 SH2 Arg 288 Trp, missense mutation
12 Exon 12 SH2 Gly 325 Glu, nonsense mutation
16 Exon 18 Kinase Thr 602 Ile, missense mutation
PH, pleckstrin homology; SH, Src homology; TH, Tec homology.
*Patients 3 and 6 are siblings.
Table 3. Infections Leading to Hospitalization in Patients with XLA
Type of infection No. of patients % of total patients
Pneumonia 13 68.4
Acute otitis media 6 31.6
Septic arthritis 5 26.3
Skin infection 5 26.3
Sepsis 4 21.1
Sinusitis 4 21.1
Acute gastroenteritis 3 15.8
Cervical lymphadenitis 3 15.8
Epididymitis 3 15.8
Meningitis 3 15.8
Osteomyelitis 2 10.5
Urinary tract infection 2 10.5
Encephalitis 1 5.3
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clinical courses of pneumonia, gastroenteritis, and
meningitis by enteroviral infection led pediatricians
to suspect immunodeficiency, and after several
tests the patients were diagnosed as XLA. A
prolonged course of illness and the development
of serious complications like bronchiectasis,
gastrointestinal bleeding, and meningoencephalitis
prompted these suspicions. For patients below age
one, it is difficult to diagnose XLA caused by
sporadic mutations until fulminant sepsis, atypical
pneumonia, and encephalitis by enterovirus occur.
Ten percent of our XLA patients were below age
one. One case was revealed as XLA by immune
studies due to recurrent acute gastroenteritis and
pneumonia presented with a prolonged clinical
course. Another case was diagnosed due to a past
medical history of encephalitis and sepsis and a
recent diagnosis of Q-fever after a full work-up
for fever of unknown origin (FUO). Each clinical
course of XLA patients and antibiotic therapies
Table 4. Clinical Courses of the Patients with XLA
Patient Type of infection
No. of
admissions
Antibiotic treatment given before IVGG
1 FUO, AOM, acute pharyngotonsillitis 4 ceftriaxone, vancomycin, ceftizoxime
2 encephalitis, sepsis, Q fever
1
ceftazidime, amikacin, tetracycline, acyclovir,
mycostatin
3 pyogenic arthritis, pleural effusion, pneumonia 2 cefoxitin, gentamicin
4 pneumonia, sinusitis 2 cefzil, amoxicillin, + clavulanate
5 encephalitis, sepsis, chronic hepatitis B,
pneumonia
10 cefotaxime, cefazolin, gentamicin, ceftriaxone,
6 osteomyelitis, pneumonia, septic arthritis 7 cefoxitin, gentamicin
7 axillary lymphadenitis, pneumonia, bronchiolitis 0 amoxicillin + clavulanic acid
8 meningoencephalitis, pneumonia, UTI, sepsis 4 ceftriaxone, ampicillin + sulbactam,
micronomicin
9 pleural effusion, pneumonia, AOM, cellulitis 7 ceftriaxone, ampicillin + sulbactam
10 osteomyelitis, bacterial meningitis, pneumonia,
septic arthritis, Tbc lymphadenitis
10 INAH, RFP, PZA, ethambutol, metronidazole,
vancomycin, ceftriaxone, cefzil
11 AOM, pneumonia, sinusitis 1 cefzil, amoxicillin + clavulanate
12 AOM, sinusitis 0 cefdinir, amoxicillin + clavulanate
13 bronchiolitis, pneumonia, AOM, Rota viral
enteritis, AGE
3 amoxicillin + clavulanate, cephapirin,
micronomycin, fluconazole
14 cellulitis, AGE, pneumonia, AOM, bronchitis 10 cefoxitin, gentamicin
15 septic arthritis, neck mass, impetigo 3 amoxicillin + clavulanate, ceftriaxone
16 recurrent pneumonia 2 ceftriaxone, amoxicillin + clavulanate,
clarythromycin
17 meningitis, encephalitis, skin infection, arthritis,
UTI, sepsis, pneumonia, tonsilitis, bronchitis
10 amoxicillin + clavulanate, ceftriaxone,
amikacin, acyclovir, fluconazole
18 septic arthritis, meningitis, AOM, pneumonia,
pulmonary tuberculosis
12 ampicillin, gentamicin, cefzil, micronomycin,
ampicillin + sulbactam, INAH, RFP, PZA,
ethambutol, streptomycin
19 pneumonia, bronchiectasis 12 cefoxitin, gentamicin, fusidic acid
INAH, isoniazid; RFP, rifampin; PZA, pyrazinamide; FUO, fever of unknown origin; AOM, acute otitis media; AGE, acute
gastroenteritis; UTI, urinary tract infection.
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given to each patient is listed in Table 4.
There were 2 cases (patients 4 and 19) in which
chronic lung diseases (CLD) developed due to
recurrent pneumonia. Despite receiving IVGG
therapy regularly since diagnosis, the patients’
CLDs have been remained and continued to be
major health problems.
Microorganisms isolated from the patients
included S. aureus, S. pneumoniae, P. aeruginosa, E.
coli, Enterovirus, Epstein-Barr virus, Aspergillus
fumigatus, Candida albicans, and M. tuberculosis.
For their routine immunizations, all XLA
patients included in our study received the live
vaccine for polio, tuberculosis, measles, mumps,
and rubella before diagnosis.
The frequency of admission varied from 0 to 12
times, but with earlier IVGG therapy there were
significantly fewer admissions (r = 0.624, p < 0.01).
There were no cases of fatal pneumonia in the
group receiving IVGG therapy, although mild
otitis media and sinusitis did occur in this group.
XLA patients were treated with IVGG (400 mg/
kg/dose) monthly to maintain a serum concentra-
tion of IgG of over 500 mg/dL.13 In spite of IVGG
therapy, there were incidents of pneumonia,
pulmonary mycobacterial infections, and upper
respiratory infections in the patients, but overall
clinical features were not severe.
Several patients also presented extra manifesta-
tions. Autoimmune diseases were observed in 6 of
the patients, 3 were diagnosed as juvenile rheuma-
toid arthritis, and 3 suffered from autoimmune
epididymitis. Hepatocellular carcinoma (HCC) was
also observed in one patient.
Two patients in the study died. Patient 5 died
of HCC which developed from liver cirrhosis due
to chronic Hepatitis B. Patient 8 was not followed-
up and was found to be dead after a phone call
inquiry. Patient 17 was neither followed-up and
thus was dropped from our survey after 2003.
Extended family histories were evaluated in 6
cases. Having a family member who had been
diagnosed as XLA was considered to have a
positive family history. Excluded from this
designation were cases in which an early death of
a family member occurred due to severe recurrent
infections.10 In two families, an older brother had
been previously diagnosed, prompting an evalua-
tion of the other member of the family. The
patient’s sibling was then diagnosed as XLA by
BTK gene sequencing, and, as a result, the
younger brother received IVGG therapy earlier
than any other patient in our study and did not
experience any severe infections. A total of 3
families received gene screening with PCR-SSCP.
As a result, in two families, the patients’ mothers
exhibited a typical mosaic pattern and in the third
family, the patient’s maternal grandmother was
normal while one maternal aunt had the same
carrier state.
DISCUSSION
An early diagnosis of XLA with immediate
initiation of therapy is crucial for ensuring good
outcomes for the affected patients.10 Delayed
diagnosis could lead to long-lasting sequelae such
as bronchiectasis, hearing loss, or liver cirrhosis
due to chronic hepatitis. BTK gene sequencing is
very useful in diagnosing XLA in cases of
overlapping clinical features like common variable
immunodeficiency, transient hypogammaglobuli-
nemia, and mixed neutropenia situations. Early
diagnoses are now being made using gene sequ-
encing techniques before overwhelming infections
occur. Though missense mutations affecting non-
conserved residues in the amino acid sequence for
each domain and mutations in noninvariant
splicing positions are less severe mutations,10 the
genotype-phenotype correlation has not been
well-characterized.4,16 The main feature of XLA is
recurrent bacterial infections due to humoral im-
munodeficiency. The disease occasionally manifests
with diverse clinical spectrums such as autoimmune
diseases or cancer. It is known to have an
X chromosome-linked inheritance pattern. However,
according to several reports, there is a positive
family history in only 30 - 50% of all XLA patients,
with the remaining cases developing as sporadic
mutations.9,10 According to the BTK gene database
(http://bioinf.uta.fi/BTKbase/types_domains.html),
a total of 620 gene mutations from 974 unrelated
families have been registered. Patients assumed to
have XLA have BTK gene mutations in 90 - 95%
of the cases and, if a mutation in BTK is revealed,
the diagnosis is confirmed.
14
This gene study is
the most useful in atypical XLA patients, whose
Jin-Kyong Chun, et al.
Yonsei Med J Vol. 49, No. 1, 2008
serum IgG concentrations are above the diagnostic
threshold and whose resulting clinical manifesta-
tions are subtle; these patients usually have a
delayed diagnosis.17 According to references, in
general, around 15 - 59% of patients have under-
gone gene studies to look for BTK mutations.9,12
In our institution, 42% of XLA patients were
genetically examined. The accepted standard
diagnosis method, based on hypogammaglo-
bulinemia and a B cell count under 2%, accounts
for only 17% of the total of XLA diagnoses.9
Around 20% of XLA patients were diagnosed on
the basis of family history, recurrent bacterial
infections, and BTK gene mutation when other
laboratory data did not fulfill diagnostic criteria.9
Another diagnostic clue is the absence of tonsils
and scanty cervical lymph nodes. The marked
paucity of cervical lymph nodes and tonsilar
tissue with recurrent otitis media is unusual and
should alert primary physicians to the possibility
of immunodeficiency.10
Fortunately, none of the patients in our study
had any negative consequences due to the live
vaccines they received as standard care prior to
diagnosis. This phenomenon might be explained
by the fact that T cell function in XLA is not
impaired, so partial immune defense mechanisms
can compensate for impaired humoral immunity.
Recently, the live polio vaccine was replaced by
an inactivated, killed vaccine, so there is now no
risk that XLA patients might develop polio
infection.12,18,19
A history of septic arthritis can be another
diagnostic clue of XLA. If physicians suspect this
disorder, they should take a thorough family
history and order an immune work-up. If patients
with septic arthritis and XLA are treated with
antibiotics alone, they show transient impro-
vement because they cannot clear the infection
without immunoglobulin replacement therapy. In
this study, patient 3 was diagnosed as XLA earlier
than other patients, so the IVGG therapy began
earlier, and the septic arthritis did not recur. He
did not suffer any functional defects as a result.
In contrast, patient 10 was diagnosed when he
was 12 years old, and IVGG therapy was delayed,
so the septic arthritis escalated to recurrent
osteomyelitis, leaving this patient with a functio-
nal defect.
In addition to septic arthritis, XLA patients often
suffer chronic enteroviral infections, persistent
rotaviral infection, chronic diarrhea by Giardia
lamblia, and other persistent infections as a result
of incomplete eradication of antigen due to
humoral immunodeficiency. In patients 13, 14,
and 18, there were several histories of admissions
because of this kind of problems, and in patient 5,
an enteroviral infection progressed to encephalitis.
All of these episodes could lead to a differential
diagnosis including XLA.19
Comparing this study with recent reports in the
US, 58% of XLA patients have a family history of
the disease, with about 34% of these patients
diagnosed without symptoms through investiga-
tions indicated by a positive family history.9 By
contrast, in this study, about 30% of XLA patients
had a family history of XLA and broad genetic
screenings could not have been performed on
cousins. In only for a select few cases genetic
screenings were performed. The reluctance to
consent to the screening could be due to a fear of
stigma against the maternal side of the family,
failure to understand the disease, and core family
trends.
The most common infections seen in XLA
patients differ slightly from country to country. In
the US, early diagnoses based on family history,
recurrent bacterial infections, and neutropenia are
prevalent, so the most frequent clinical feature is
otitis media. This is a relatively mild symptom
compared with severe life threatening infections
suffered by other XLA patients.
9
Other common
infections are pneumonia, sinusitis, and gastro-
enteritis. In the cases in this study, fulminant
pneumonia and septic arthritis were the most
common. Other common infections were skin
infections and otitis media. Immune work-ups
were done in cases of unusual recurrent infections
such as pseudomonal sepsis, staphylococcal sepsis,
and perianal abscess.10
Early IVGG replacement therapy decreased the
rates of admission and morbidity for chronic
complications, such as bronchiectasis and chronic
lung disease, and prevented fatal complications
like meningoencephalitis. According to one report,
appropriate IV immunoglobulin replacement
therapy should be started at 6 to 8 weeks of age
because around 25% of the XLA patients show
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clinical symptoms before 4 months of age.20 After
the infant period, more than 3 occurrences of otitis
media and sinusitis, the absence of tonsils, and the
presence of scanty cervical lymph nodes are
indications to check immunoglobulin serum
levels. If the levels of more than two types of
immunoglobulin are decreased, XLA should be
suspected.9 Otolaryngologists should also be
mindful of this disease when they are caring for
otitis media and sinusitis, the most frequent
bacterial infections in childhood.
The incidence of XLA seems to be increasing
throughout the world.9 In our study, from 1985 -
2000, 11 cases were observed; from 2000 - 2006, 8
cases were observed. This phenomenon may be
due to increasing rates of diagnosis since the
implementation of genetic analysis. One patient in
our study had only recurrent upper respiratory
infections and otitis media as symptoms of the
underlying problem and had no other serious
infections. However, his observant primary care
physician ordered the immunologic screening test
and referred him to this hospital.
According to a recent study done in the US in
2006,9 a total of 201 XLA patients were entered in
the registry. Seventeen of those patients died.
Fourteen of the patients were dead at the time
they were entered in the registry (before 1999),
and the additional 3 patients died (3.75%) during
the follow-up period (1999 - 2004). This is a
relatively low rate compared with those of other
cellular immunodeficiencies. The most common
cause of death was chronic enteroviral infection,
followed by CLD and hepatitis. In this study, one
patient died of hepatocellular carcinoma secondary
to Hepatitis B virus (HBV). HBV infection is
emerging as a life-threatening infection in long
term follow-up of XLA patients. If the patient has
a family member who is an HBV carrier, routine
monitoring of serum HBV surface antigen is
necessary, especially in areas like South Korea
where HBV is endemic.
Respiratory tract infections are prominent
clinical problem observed during follow-up despite
immunoglobulin replacement therapy. The overall
probability of developing CLD reached about 80%
after 17 years of follow-up.13 In our study, following
patients over 20 years, almost all XLA patients
have experienced intermittent mild sinusitis and
bronchitis despite IVGG. No severe CLD was
found in our study.
XLA is a well-known immunodeficiency disease
for which early diagnosis and proper manage-
ment is possible if physicians have a high index
of suspicion for this disease. Although gene
defects are known, clinical phenotypes are different
for the same mutation and several diseases can be
presented combining with XLA, so further studies
should tell us about these findings. To advance
the study of XLA, including gene analysis and
new treatment modalities, the joint efforts of
several referral centers would be required.
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